{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-22-000194","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.617375+00:00","generated_at":"2026-06-23T00:45:35.228433+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BMY Q3 revenue $11.2B (-3% YoY), GAAP EPS $0.75, Non-GAAP $1.99","bullets":["Revenue $11.2B, down 3% vs Q3 2021; U.S. revenue up 9% to $7.9B, international down 24% to $3.3B.","GAAP EPS $0.75, Non-GAAP EPS $1.99; non-GAAP excludes amortization and acquired IPRD charges.","In-line and new product portfolio grew 8% to $8.6B (13% ex-FX); Revlimid fell 28% to $2.4B.","Completed Turning Point acquisition; FDA approved Sotyktu for plaque psoriasis in September.","Adjusted 2022 GAAP EPS guidance; reaffirmed non-GAAP EPS guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-22-000194","json":"https://secwatch.observer/filing/0000014272-22-000194.json","markdown":"https://secwatch.observer/filing/0000014272-22-000194.md","text":"https://secwatch.observer/filing/0000014272-22-000194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427222000194/0000014272-22-000194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427222000194/bmy-20221025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:45:35.228433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}